Literature DB >> 11742492

Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.

Y Shou1, T Hirano, Y Gong, Y Kato, K Yoshida, T Ohira, N Ikeda, C Konaka, Y Ebihara, F Zhao, H Kato.   

Abstract

We attempted to investigate immunohistochemical expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PD-ECGF), c-erbB-2, matrix metalloproteinase-2 (MMP-2), and MMP-9 using surgical specimens of 119 non-small-cell lung carcinoma (NSCLC) cases and to evaluate the relationship between the expression levels of each molecule and clinicopathological factors or prognosis. VEGF expression levels were significantly associated with the local invasion (P = 0.0001), lymph node involvement (pN-factor) (P = 0.0019), pathological stage (p-stage) (P = 0.0027) and lymphatic permeation (P = 0.0389). PD-ECGF expression levels were associated with pN-factor (P = 0.0347). MMP-2 expression levels were associated with pN-factor (P = 0.004) and lymphatic permeation (P = 0.0056). Also, MMP-9 expression levels showed a significant correlation to local invasion (P = 0.0012), pN-factor (P = 0.0093) and p-stage (P = 0.0142). Multivariate analysis showed VEGF to be the most related to local invasion (P = 0.0084), and MMP-2 was the only factor with significant independent impact on lymphatic permeation (P = 0.0228). Furthermore, log-rank analysis showed significant association with poor survival by VEGF, bFGF, MMP-2 and MMP-9. Especially, combined overexpression of VEGF and MMP-2 revealed poor prognosis, our study might provide a basis for the better evaluation of biological characteristics and a new therapeutic strategy based on chemotherapy. (c) 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742492      PMCID: PMC2363988          DOI: 10.1054/bjoc.2001.2137

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  54 in total

1.  The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining.

Authors:  Y Sato; K Mukai; S Watanabe; M Goto; Y Shimosato
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

2.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

3.  Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma.

Authors:  M Tateishi; T Ishida; T Mitsudomi; S Kaneko; K Sugimachi
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

Review 4.  Molecular aspects of tumor cell invasion and metastasis.

Authors:  S Aznavoorian; A N Murphy; W G Stetler-Stevenson; L A Liotta
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

5.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma.

Authors:  P D Brown; R E Bloxidge; N S Stuart; K C Gatter; J Carmichael
Journal:  J Natl Cancer Inst       Date:  1993-04-07       Impact factor: 13.506

6.  Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases.

Authors:  M el-Torky; F el-Zeky; J C Hall
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

7.  Tumor angiogenesis and recurrence in stage I non-small cell lung cancer.

Authors:  Y Ohta; Y Tomita; M Oda; S Watanabe; S Murakami; Y Watanabe
Journal:  Ann Thorac Surg       Date:  1999-09       Impact factor: 4.330

8.  Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients.

Authors:  S Duensing; J Grosse; J Atzpodien
Journal:  Anticancer Res       Date:  1995 Sep-Oct       Impact factor: 2.480

9.  p185neu expression in human lung adenocarcinomas predicts shortened survival.

Authors:  J A Kern; D A Schwartz; J E Nordberg; D B Weiner; M I Greene; L Torney; R A Robinson
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

10.  Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas.

Authors:  T Ohta; M Yamamoto; M Numata; S Iseki; Y Tsukioka; T Miyashita; M Kayahara; T Nagakawa; I Miyazaki; K Nishikawa; Y Yoshitake
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  19 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.

Authors:  Yuri Shimanuki; Kazuhisa Takahashi; Ri Cui; Satoshi Hori; Fumiyuki Takahashi; Hideaki Miyamoto; Yoshinosuke Fukurchi
Journal:  Lung       Date:  2005 Jan-Feb       Impact factor: 2.584

3.  Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis.

Authors:  Jiying Wang; Yong Cai
Journal:  Tumour Biol       Date:  2012-06-21

Review 4.  Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.

Authors:  Christine L Hann; Charles M Rudin
Journal:  Trends Mol Med       Date:  2007-02-26       Impact factor: 11.951

5.  Relationship between matrix metalloproteinase 2 and lung cancer progression.

Authors:  Chun-Bao Guo; Shan Wang; Chun Deng; Dian-Liang Zhang; Fu-Ling Wang; Xian-Qing Jin
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

6.  Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.

Authors:  Cigdem Usul Afsar; Berksoy Sahin; Meral Gunaldi; Emine Kılıc Bagir; Derya Gumurdulu; Refik Burgut; Melek Erkisi; Ismail Oguz Kara; Semra Paydas; Feryal Karaca; Vehbi Ercolak
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer.

Authors:  Carmen Behrens; Heather Y Lin; J Jack Lee; Maria Gabriela Raso; Waun Ki Hong; Ignacio I Wistuba; Reuben Lotan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

8.  Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours.

Authors:  Mei Lin Tan; Peter F M Choong; Crispin R Dass
Journal:  Cancer Cell Int       Date:  2010-03-24       Impact factor: 5.722

Review 9.  The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature.

Authors:  A-P Meert; B Martin; M Paesmans; T Berghmans; C Mascaux; J-M Verdebout; P Delmotte; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

10.  FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.

Authors:  Janani Ravi; Amita Sneh; Konstantin Shilo; Mohd W Nasser; Ramesh K Ganju
Journal:  Oncotarget       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.